Type 2 diabetes (T2D) is a complex disease whose management requires various medical and lifestyle interventions. Recent discoveries across therapeutic areas have reshaped the clinical research landscape. Even so, how can novel and existing treatments be favorably positioned in an ever-changing environment? This paper explores the convergence of therapeutic areas and regulatory landscapes in T2D and obesity.
Authors:
MarieElena Cordisco
Senior Director Therapeutic Strategy Lead Metabolic
Michael Murphy, MD, PhD
Chief Medical and Scientific Officer
Peyton Sandroni, PhD
Fellow, Clinical Research Methodology and Translational Medicine
